SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study

SELLAS Life Sciences Group, Inc. announced that the first acute myeloid leukemia patient has enrolled in the fifth dose level cohort, out of the expected six dose cohorts, in the ongoing Phase I dose-escalating clinical trial with SELLAS’ newly in-licensed GFH009 asset.